Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Majority of Engaged Couples Register for Wedding Gifts Online, Personalizing Their Registries for Their Unique Lifestyles, According to The Knot 2019 Registry Study

Published

on

Reading Time: 5 minutes

Couples Registered on The Knot Registry Are Choosing Household Items
From Retailers and Cash for Their Dream Honeymoon, New Home, Adoption
and Experiences

NEW YORK–(BUSINESS WIRE)–Today, The
Knot
—the #1 wedding planning and registry
resource in the US—released findings from The Knot 2019 Wedding Registry
Study, the largest and most comprehensive wedding registry study of
engaged and recently married couples in America. The study unveiled how
couples are curating registries that are as unique and personalized as
the wedding itself, while leveraging multiple gift options for their
soon-to-be married lives. The majority of couples (60%) set up their
primary registries online (up from 33% in 2013) and almost all (97%, up
from 81% in 2013) manage their registries digitally.

The registry journey is an exciting part of wedding planning where
couples tend to discuss their personal styles, values and what their
future looks like as they decide on the products, experiences and funds
they’ll want to start their new life together,” said Kristen Maxwell
Cooper, editor in chief of The Knot. “With The
Knot Registry
, there are no limits on what you can register for,
whether it be a kayak for the adventurous couple from their favorite
retailer, a cash fund for a family car or IVF, or a charity that’s close
to the couple’s heart. And when couples sync The Knot Registry with
their personal
wedding website
, guests can easily find and shop for everything all
in one place.”

Couples are choosing their favorite retail products (97%), cash funds
for their future (20%) and charities (11%) on The Knot Registry.
Kitchenware continues to be the most popular registry category, with
bakeware (87%), cookware (84%), kitchen appliances (82%) and kitchen
accessories (81%) being the most popular must-haves. According to The
Knot 2019 Registry Study, cash registries are on the rise (from 27% in
2017 to 37% in 2019), with the average cash registry receiving $1,863 in
guest contributions. Cash registries help couples fund everything from a
down payment on a new home to honeymoon excursions—or even a lifetime
supply of sriracha! The majority of couples on The Knot Registry create
cash funds to help pay for honeymoon-related expenses (55%). Other
popular cash fund categories on The Knot Registry include funds for
dining; food and drink experiences (15%); household-related expenses
(15%); and personal hobbies and interests (9%) for the newlyweds.

The Most Popular Registry Items on The Knot
Registry

Wedding registries, on average, feature 111 different items and have a
total value of $4,695. To-be-weds are setting up, on average, two to
three registries, with retail registries remaining the most popular
choice among couples.

The Knot Registry is the most trusted and comprehensive all-in-one
registry choice for couples in the US. With options from homewares and
electronics to cash funds and charity, couples are able to personalize
their wedding registry to fit their needs and help them start the next
chapter of their lives together.

Couples are using their wedding registries to give back, with 11%
adopting a charity using The
Knot Gifts Back
, a proprietary charity registry program that allows
couples to attach nonprofits to their retail wedding registries. With
each registry gift purchase made through The Knot Registry, The Knot
donates a portion of that gift in the couple’s name to the charity of
their choice.

Top 5 Most Popular Products Registered for on The Knot Registry:

Top Registry Must-Haves for 2019 From The Knot Trusted Editors:

Most Popular Cash Funds Registered for on The Knot Registry:

1. Honeymoon-related expenses

2. Dining and food experiences

3. Funds for a down payment on a home

4. Physical and mental wellness

5. Continued learning and recreational classes

Top 5 Most Popular Charity Registry Selections on The Knot Gifts Back:

1. Humane
Society of the United States

2. St.
Jude’s Children’s Research Hospital

3. American
Cancer Society

4. Make-A-Wish
Foundation of America

5. VOW

Couples using The Knot Registry are making a big impact. For example, in
2018, couples using The Knot Registry raised enough money for St. Jude’s
Children’s Research Hospital to provide 2,032 new toys for hospital play
areas and recreational areas at St. Jude housing facilities. Couples who
selected Feeding America as their charity of choice on The Knot Gifts
Back charity registry program provided 9,680 meals to families in need
through the funds raised by their wedding gift purchases. The Knot Gifts
Back is free for couples to opt into and doesn’t cost anything for
guests. The Knot is honored to offer a charity registry program that
simultaneously benefits to-be-wed couples and those in need.

For the full list of most popular registry items, experiences and
charities, plus recommendations from The Knot Editors, see The Knot
Registry Awards at https://www.theknot.com/registry-awards.

Top Wedding Registry Trends From The Knot 2019
Registry Study

RETAIL REGISTRIES CONTINUE TO REMAIN MOST POPULAR. Bakeware,
blenders and bed sheets on wedding registries aren’t going anywhere. The
majority of US couples (80%) have at least one retail registry. On
average, couples begin curating their registry about seven months before
their wedding day. Most to-be-weds (60%) curate registries with the goal
of upgrading their current household items, such as cookware, bakeware,
sheets and towels. When deciding which retailers to create registries
with, couples consider the products available (93%); variety of price
points offered (88%); if the retailer offers online management tools
(88%); how affordable the products are (84%); and if there’s a good
return/exchange policy (83%).

HONEYMOON REGISTRIES TAKE FLIGHT; NEARLY 1 IN 10 COUPLES CONSIDER
THEIR HONEYMOON REGISTRY THEIR PRIMARY REGISTRY.
Millennial couples
are all about experiences, and study data shows that newlyweds stress
the importance of having a honeymoon. Since 2010, honeymoon registries
have nearly tripled in popularity, with one in three (29%) to-be-wed
couples creating one. On average, couples receive $1,562 from guests to
put toward their honeymoon-related expenses, from first-class flight
upgrades to wine tours in Tuscany. While retailer registries continue to
be the most popular selection as a primary registry, honeymoon
registries are gaining traction, with nearly 1 in 10 couples (9%)
considering their honeymoon registry their primary registry.

MILLENNIAL COUPLES PRIORITIZE DIGITAL REGISTRY CREATION AND
MANAGEMENT.
From finding
inspiration
to booking
vendors
, millennials are turning to technology for all aspects of
wedding planning—and creating their registry is no exception. Nearly two
in three couples (60%) set up their primary registries online (up from
33% in 2013) and almost all (97%, up from 81% in 2013) manage their
registries digitally. Nearly 9 in 10 couples (88%) report prioritizing
retailers that offer registry management tools across digital platforms.
Mobile registry management tripled in popularity in recent years, with 4
in 10 couples (39%) reporting they managed their registry almost
exclusively from their mobile devices in 2018 (up from 13% in 2014),
using apps like the The
Knot App
.

WHILE SETTING UP WEDDING REGISTRIES, COUPLES THINK OF THEIR GUESTS. When
determining where to register, nearly all to-be-weds (98%) report being
concerned with how easy gifting and shopping off their registry will be
for guests. In order to streamline all the information about their
wedding celebration—including where to find and purchase wedding
gifts—the majority of couples (83%) report using their personal wedding
website
to share all the necessary information. The personal wedding
website is the most popular way for guests to find information about an
upcoming wedding, including finding and purchasing a gift for the
newlyweds.

1Source The Knot 2018 Guest Study

About The Knot

The Knot is the nation’s leading multiplatform wedding resource offering
a seamless, all-in-one planning experience—from finding inspiration and
local vendors to creating and managing all guest experiences, wedding
registries and more. The trusted brand reaches a majority of engaged
couples in the US through the #1 wedding planning website TheKnot.com
and #1 iOS and Android mobile app The Knot Wedding Planner, The Knot
national and local wedding magazines, and The Knot book series. Since
its inception, The Knot has inspired approximately 25 million couples to
plan a wedding that’s uniquely them. Visit The Knot online at TheKnot.com
and follow on social media: Facebook.com/TheKnot
and @TheKnot onTwitter,
Pinterest
and Instagram.

Contacts

MEDIA
Melissa Bach
Senior Director, Public Relations &
Brand Marketing
[email protected]


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Innocan

Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain

Published

on

innocan-pharma-initiates-fda-approval-process-for-liposome-injection-therapy-for-chronic-pain

With its submission of a Pre-IND Meeting Request Letter, Innocan initiates the regulatory process with the U.S. Food and Drug Administration (FDA) for the approval of its prolonged CBD release technology for human use

HERZLIYA, Israel and CALGARY, AB, April 22, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), is pleased to announce that is has reached a key milestone: the Company submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for Innocan’s Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain.

With the global market for pain therapeutics widely expected to exceed US$100 billion by 2032[1], LPT therapy which requires only one single monthly subcutaneous injection, is positioned as a highly attractive alternative to opioid-based approaches. Opioids have and continue to take a significant human toll in recent years, with more than three-quarters of drug overdose deaths in the United States involving opioids, according to the United States Center for Disease Control and Prevention[2].

Innocan’s therapy has shown consistent efficacy in multiple pre-clinical trials in recent years of it’s LPT-CBD injectable treatment through prolonged and controlled release of CBD in animals with chronic pain conditions. Innocan’s Pre-IND Meeting Request Letter to the FDA is a key milestone and important first step in seeking approval of its LPT-CBD therapy for use in humans. At the Pre-IND meeting, the objective will be to obtain guidance from the FDA on the preclinical and clinical development plan, enabling the initiation of an Investigational New Drug (IND) program in the United States.

Iris Bincovich, CEO of Innocan, commented: “We are extremely excited to embark on this next stage in the development of LPT-CBD injectables, this is a major Milestone for Innocan Pharma. We have invested significant effort and many thousands of person-hours in its research and development, accumulating a wealth of preclinical data that will serve as the foundation for our participation in the FDA process. This is a key milestone for Innocan and marks our first step towards the FDA’s recognition of our technology. We see significant potential for our therapy, with an addressable market for pain management therapeutics expected to exceed US $100 billion by 2032, and we look forward to tapping that.

Dr. Joseph Pergolizzi, Innocan’s FDA Advisory Board Member, added:

“We have worked hard to catalogue the data collected as part of our animal LPT therapy testing program and prepare it for the FDA. We look forward to working under FDA guidance, with the goal of completing the review process as quickly and efficiently as possible. We believe that Innocan’s unique treatment method, if and when it should become FDA-approved has the potential of being a highly valuable non-opioid addition in the medical arsenal of the management of chronic pain.”

About Innocan

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for: Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment, Innocan has established a joint venture by the name of BI Sky Global Ltd. that focuses on advanced targeted online sales. https://innocanpharma.com/

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO

+1-516-210-4025

+972-54-3012842

+442037699377
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Cautionary note regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company’s products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

[1] https://www.gminsights.com/industry-analysis/pain-management-drugs-market

[2] https://www.cdc.gov/opioids/data/index.html

Logo – https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-initiates-fda-approval-process-for-liposome-injection-therapy-for-chronic-pain-302122779.html

Continue Reading

Curaleaf

Curaleaf Completes Acquisition of Northern Green Canada

Published

on

curaleaf-completes-acquisition-of-northern-green-canada

Bolsters Company’s Advantage in Several Key Emerging Markets, including Australia, New Zealand, Germany, Poland and the United Kingdom

NEW YORK, April 22, 2024 /PRNewswire/ — Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading international provider of consumer cannabis products, announced today the closing of its acquisition of Northern Green Canada (“NGC”), a vertically integrated Canadian licensed cannabis producer focused primarily on expanding in the international market through its EU-GMP certification. The accretive acquisition amplifies the Company’s strategic advantage in established European markets including Germany, Poland and the United Kingdom and provides a foothold in the emerging markets of Australia and New Zealand.

Integrating NGC’s international operation will equip Curaleaf with a secure and consistent high quality, non-irradiated, indoor EU-GMP flower supply, essential to maintaining its leading positions in Germany, the United Kingdom and Poland.

“We are thrilled to welcome NGC formally to the Curaleaf family of global brands,” said Boris Jordan, Founder and Executive Chairman of Curaleaf. “This is an incredibly important deal for our international expansion strategy, as we’ll be able to bolster our supply of high quality EU-GMP certified flower immediately to key European markets as well as enter the fast-growing markets of Australia and New Zealand.”

The global cannabis market is projected to generate $55 billion in sales by 2027. Emerging markets beyond the United States and Canada, including Germany, Australia and New Zealand are expected to contribute $6.3 billion of the $55 billion projection.

Terms of the acquisition of NGC include an initial payment at closing of the Company’s Subordinate Voting Shares valued at approximately US $16 million, subject to a typical post-closing adjustment. An earnout may also be paid in 2025 based upon 2024 performance of NGC’s operations, up to 50% of which will be cash and the rest paid in additional Subordinate Voting Shares. The issuance of Subordinate Voting Shares in connection with the acquisition of NGC has been conditionally approved by the Toronto Stock Exchange, subject to fulfilling customary listing conditions.

About Curaleaf Holdings
Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf”) is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, Grassroots, JAMS, Find and Zero Proof provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is the largest vertically integrated cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Toronto Stock Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.

Forward Looking Statements
This media advisory contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, “expects” or, “proposed”, “is expected”, “intends”, “anticipates”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward-looking statements and information concerning the expected benefits of the acquisition of NGC, and the Company’s planned expansion on internal markets, the Company’s anticipated strategic advantages in European markets and emerging markets, the integration of NGC’s internal operations, the anticipated global cannabis market, and the listing of shares issuable in connection with the acquisition on the Toronto Stock Exchange. Such forward-looking statements and information reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company with respect to the matters described in this new release, including the Company’s ability to successfully realize the expected benefits of the acquisition, and the Company’s ability to fulfil the listing conditions imposed by the Toronto Stock Exchange. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including the failure to realize the expected benefits of the acquisition, or the Company’s failure to fulfil the listing conditions imposed by the Toronto Stock Exchange. Additional information about these assumptions and risks and uncertainties is contained under “Risk Factors and Uncertainties” in the Company’s latest annual information form filed on March 6, 2024, which is available under the Company’s SEDAR profile at http://www.sedar.com, and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The Toronto Stock Exchange has not reviewed, approved or disapproved the content of this news release.

INVESTOR CONTACT
Curaleaf Holdings, Inc.
Camilo Lyon, Chief Investment Officer
[email protected]

MEDIA CONTACT
Curaleaf Holdings, Inc.
Tracy Brady, SVP Corporate Communications
[email protected]

View original content:https://www.prnewswire.co.uk/news-releases/curaleaf-completes-acquisition-of-northern-green-canada-302123010.html

Continue Reading

Cannabis

Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect

Published

on

Continue Reading

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania